Taysha Gene Therapies (TSHA) Tops Q2 EPS by 7c

Taysha Gene Therapies (NASDAQ: TSHA) reported Q2 EPS of ($0.09), $0.07 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $1.11 million versus the consensus estimate of $2.76 million.

For earnings history and earnings-related data on Taysha Gene Therapies (TSHA) click here.

You May Also Be Interested In

• Assurant (AIZ) is Piper Sandler's Weekly Focus Idea
• TD Cowen: 'Infineon Technologies AG (IFX:GR) (IFNNY) is a Top Pick'
• BrewDog bars report double-digit sales growth during FIFA World Cup